Bay Area man who injected himself with venom hundreds of times could revolutionize snakebite treatment
Tim Friede's unique exposure to snake venom has led to the development of an antivenom for 19 snake species, showcasing new possibilities in snakebite treatment.
Bay Area man who injected himself with venom hundreds of times could revolutionize snakebite treatment
Tim Friede's unique exposure to snake venom has led to the development of an antivenom for 19 snake species, showcasing new possibilities in snakebite treatment.
A Harvard Scientist's Tuberculosis Research Is Threatened by Trump's Cuts
The Trump administration's freeze on research funding critically impacts Harvard's tuberculosis research, signaling threats to scientific inquiry at elite universities.
"Current understanding suggests that somatic hypermutation (SHM) continues at a constant rate per division, so that the highest-affinity B cells accumulate more mutations than their lower affinity counterparts."
Can Adults Develop Seasonal Allergies? Symptoms and Treatments, Explained
The onset of seasonal allergies in adults is becoming common, with symptoms often mistaken for colds. They can develop at any age, especially in the 20s, 30s, and 40s.
COVID-flu vaccine could provide broad, lasting protection | Cornell Chronicle
A new vaccine platform from Cornell researchers offers longer-lasting protection against COVID-19 and influenza, showing promising results in mouse models.
Stanford researchers' flu vaccine breakthrough could help US fight bird flu
Stanford researchers have created a stronger flu vaccine that aims to protect against multiple strains, potentially including bird flu, using a novel molecular approach.
COVID-flu vaccine could provide broad, lasting protection | Cornell Chronicle
A new vaccine platform from Cornell researchers offers longer-lasting protection against COVID-19 and influenza, showing promising results in mouse models.
Stanford researchers' flu vaccine breakthrough could help US fight bird flu
Stanford researchers have created a stronger flu vaccine that aims to protect against multiple strains, potentially including bird flu, using a novel molecular approach.
AbbVie (ABBV) Earnings Live: Why The Stock Is Up Big Today
AbbVie's fourth-quarter results exceeded expectations, highlighting strong performance in immunology drugs Skyrizi and Rinvoq, with projected combined sales of $31 billion by 2029.